Reciprocal regulation between m6 A modifications and non-coding RNAs: emerging roles in cancer therapeutic resistance DOI Creative Commons
Dan Fan, Yan Shang, Y. Cong

и другие.

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Май 25, 2025

In recent years, the interplay between N6-methyladenosine (m6A) modifications and non-coding RNAs (ncRNAs) has emerged as a pivotal research area, owing to their crucial involvement in pathophysiological mechanisms underlying various diseases. A significant hurdle cancer therapy is therapeutic resistance, which frequently contributes adverse patient outcomes. Recent investigations have underscored vital role that interactions m6A ncRNAs play mediating resistance via MAPK, PI3K/Akt/mTOR, Wnt/β-catenin, HIPPO, NF-κB pathways. This review elucidates how these drive tumor by modulating By dissecting regulatory dynamics context of this aims deepen understanding m6A-ncRNA interaction identify potential targets improve treatment efficacy.

Язык: Английский

hnRNPA2B1 drives colorectal cancer progression via the circCDYL/EIF4A3/PHF8 axis DOI Creative Commons
Ying-hao SUN,

Jin‐Fu Wang,

Xizhuo Sun

и другие.

The Kaohsiung Journal of Medical Sciences, Год журнала: 2025, Номер unknown

Опубликована: Янв. 15, 2025

The RNA-binding protein hnRNPA2B1 acts as an m6A reader and plays a role in tumor development. This study investigates the potential mechanism of colorectal cancer (CRC) progression. expression profiles hnRNPA2B1, circCDYL, PHF8 CRC cell lines were analyzed. Following si-hnRNPA2B1 transfection, proliferation, invasion, migration evaluated by CCK-8 Transwell. CDYL was detected after actinomycin D RNase R treatment. RIP conducted to assess enrichment on circCDYL. RNA pull-down assays established interaction between circCDYL EIF4A3/PHF8. EIF4A3 using RT-qPCR Western blot techniques. displayed high levels, whereas showed low levels cells. Inhibition reduced migration, invasion. mechanistically elevated level while decreasing its expression, which turn binding enhanced expression. In summary, hnRNPA2B1-mediated modification decreases inhibits with EIF4A3, enhances ultimately facilitates

Язык: Английский

Процитировано

1
CircRNA circACTN4 Promotes the Progression of Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma by Targeting the miR-424-5p/NCAPG/Wnt Axis DOI Creative Commons
Jie Shan,

Junxia Pu,

Xiaohao Chen

и другие.

Clinical and Experimental Medicine, Год журнала: 2025, Номер 25(1)

Опубликована: Фев. 1, 2025

Growing research reveals that circular RNAs (circRNAs) play a major part in the progression and development of cancer. Here, we investigated oncogenic function regulatory mechanisms circRNA circACTN4 hepatocellular carcinoma (HCC), particularly tumor epithelial-mesenchymal transition (EMT). In vitro functional assays (Cell Counting Kit 8, TUNEL, scratch wound healing, invasion assays) HCC cell lines, alongside vivo analyses subcutaneous tumors nude model mice, were employed to assess impact on proliferation. Interactions concerning circACTN4, microRNA (miR)-424-5p, non-SMC condensing I complex subunit G (NCAPG) have been assessed deploying luciferase reporter also quantitative reverse transcription PCR investigation transcripts tissues. Findings indicated high expression HCC, promoted proliferation, while inhibiting apoptosis cells, correlated with poor prognosis. Mechanistically, served as rival internal RNA for miR-424 5p, controlling NCAPG level initiating Wnt/β-catenin signaling routes, which turn impacted EMT machinery HCC. According our surveys, circACTN4/miR-424 5p/NCAPG axis could be an intriguing candidate therapy address treatment

Язык: Английский

Процитировано

1
Exosomal circular RNAs in tumor microenvironment: An emphasis on signaling pathways and clinical opportunities DOI Creative Commons
Junshu Li, Wencheng Zhou, Huiling Wang

и другие.

MedComm, Год журнала: 2024, Номер 5(12)

Опубликована: Ноя. 24, 2024

Exosomes can regulate the malignant progression of tumors by carrying a variety genetic information and transmitting it to target cells. Recent studies indicate that exosomal circular RNAs (circRNAs) multiple biological processes in carcinogenesis, such as tumor growth, metastasis, epithelial-mesenchymal transition, drug resistance, autophagy, metabolism, angiogenesis, immune escape. In microenvironment (TME), circRNAs be transferred among cells, endothelial cancer-associated fibroblasts, microbiota, affecting initiation progression. Due high stability widespread presence circRNAs, they hold promise biomarkers for diagnosis prognosis prediction blood urine. addition, designing nanoparticles targeting utilizing derived from cells or stem provide new strategies cancer therapy. this review, we examined crucial role regulating tumor-related signaling pathways summarized transmission between various types their impact on TME. Finally, our review highlights potential diagnostic prognostic biomarkers, well suggesting clinical

Язык: Английский

Процитировано

6
Cross-talk between circRNAs and m6A modifications in solid tumors DOI Creative Commons

Fenfang Liu,

Wendong Gu, Yingjie Shao

и другие.

Journal of Translational Medicine, Год журнала: 2024, Номер 22(1)

Опубликована: Июль 29, 2024

Abstract Circular RNAs (circRNAs) possess unique biological properties and distribution characteristics that enable a variety of functions. N6-methyladenosine (m6A), prevalent epigenetic modification in organisms, is regulated by factors including methyltransferases (writers), demethylases (erasers), m6A-binding proteins (readers). These play critical roles various pathophysiological processes. There growing evidence m6A modifications are common within circRNAs, affecting their synthesis, translation, translocation, degradation, stability. Additionally, circRNAs regulate processes influence modifications. This review explores the metabolism functions interactions, specific regulatory mechanisms different tumors, offering insights into m6A-circRNA interaction cancer.

Язык: Английский

Процитировано

4
Bola-Amphiphilic Dendrimer Enhances Imatinib to Target Metastatic Ovarian Cancer via β-Catenin-HRP2 Signaling Axis DOI Creative Commons
Zeyu Shi, Margarita Artemenko,

Weiyu Yu

и другие.

ACS Applied Materials & Interfaces, Год журнала: 2025, Номер 17(2), С. 2884 - 2898

Опубликована: Янв. 3, 2025

Ovarian cancer is the leading cause of death among all gynecological malignancies, and drug resistance renders current chemotherapy agents ineffective for patients with advanced metastatic tumors. We report an effective treatment strategy targeting ovarian involving a nanoformulation (Bola/IM)─bola-amphiphilic dendrimer (Bola)-encapsulated imatinib (IM)─to target critical mediator stem cells (CSCs) CD117 (c-Kit). Bola/IM offered significantly more CSCs compared to IM alone, through novel tumor-specific β-catenin/HRP2 axis, allowing potent inhibition cell survival, stemness, metastasis in drug-resistant cells. Promising results were also obtained clinically relevant patient-derived ascites organoids alongside high tumor-oriented accumulation favorable pharmacokinetic properties mouse models. Furthermore, displayed synergistic anticancer activity when combined first-line chemotherapeutic cisplatin xenograft models without any adverse effects. Our findings support use as empower IM, providing targeted cancer. study thus represents significant advancement toward addressing unmet medical need improved therapies this challenging disease.

Язык: Английский

Процитировано

0
Targeting m6A RNA Modification in Tumor Therapeutics DOI Creative Commons
Zhenwei Mao, Min Li, Shengjun Wang

и другие.

Current Oncology, Год журнала: 2025, Номер 32(3), С. 159 - 159

Опубликована: Март 11, 2025

The prevalent eukaryotic RNA modification N6-methyladenosine (m6A), which is distributed in more than 50% of cases, has demonstrated significant implications both normal development and disease progression, particularly the context cancer. This review aims to discuss potential efficacy targeting tumor cells through modulation m6A levels. Specifically, we how upregulation or downregulation integral specific targets effective treating different types patients. Additionally, will cover factors influencing treatment. Our focus on impact mRNA genes assess its as a therapeutic strategy for tumors. Despite challenges involved, further research tumors integration with existing therapy approaches warranted.

Язык: Английский

Процитировано

0
Emerging roles of exosomal circRNAs in non-small cell lung cancer DOI Creative Commons
Hong Yin, Jiaxiao Shi, Shaoling Li

и другие.

Journal of Translational Medicine, Год журнала: 2025, Номер 23(1)

Опубликована: Апрель 30, 2025

Despite the prevalence of non-small cell lung cancer (NSCLC) is high, limited early detection and management these tumors are restricted since there an absence reliable precise diagnostic biomarkers therapeutic targets. Exosomes transport functional molecules for facilitating intercellular communication, especially in tumor microenvironment, indicating their potential as Circular RNA (circRNA), a type non-coding possessing covalently closed loop structure, substantial abundance, tissue-specific expression patterns, stably enriched exosomes. In recent years, significant breakthroughs have been made research on exosomal circRNA NSCLC. This review briefly introduces biogenesis, characterizations, functions circRNAs exosomes, systematically describes biological mechanisms addition, this study summarizes role progression NSCLC discusses clinical significance targets

Язык: Английский

Процитировано

0
Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy DOI Creative Commons
Zheng Gong, Cheng Cheng, Chaonan Sun

и другие.

Journal of Experimental & Clinical Cancer Research, Год журнала: 2025, Номер 44(1)

Опубликована: Май 2, 2025

Abstract Extracellular vesicles (EVs), particularly engineered variants, have emerged as promising tools in cancer immunotherapy due to their inherent ability modulate immune responses and deliver therapeutic agents with high specificity minimal toxicity. These nanometer-sized vesicles, which include exosomes (Exos) other subtypes, naturally participate intercellular communication are capable of carrying a diverse range bioactive molecules, including proteins, lipids, RNAs, metabolites. Recent advancements the biogenesis EVs, such strategies modify surface characteristics cargo, significantly expanded potential effective vehicles for targeted therapies. Tailoring contents incorporating immunomodulatory molecules or gene-editing (GETs), has shown outcomes enhancing anti-tumor immunity overcoming immunosuppressive tumor microenvironment (TME). Moreover, optimizing delivery mechanisms, through both passive active targeting strategies, is crucial improving clinical efficacy EV-based This review provides an overview recent developments engineering EVs immunotherapy, focusing on biogenesis, methods content customization, innovations cargo delivery. Additionally, addresses challenges associated translation therapies, issues related scalability, safety, By offering insights into current state field identifying key areas future research, this aims advance application treatment.

Язык: Английский

Процитировано

0
Reciprocal regulation between m6 A modifications and non-coding RNAs: emerging roles in cancer therapeutic resistance DOI Creative Commons
Dan Fan, Yan Shang, Y. Cong

и другие.

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Май 25, 2025

In recent years, the interplay between N6-methyladenosine (m6A) modifications and non-coding RNAs (ncRNAs) has emerged as a pivotal research area, owing to their crucial involvement in pathophysiological mechanisms underlying various diseases. A significant hurdle cancer therapy is therapeutic resistance, which frequently contributes adverse patient outcomes. Recent investigations have underscored vital role that interactions m6A ncRNAs play mediating resistance via MAPK, PI3K/Akt/mTOR, Wnt/β-catenin, HIPPO, NF-κB pathways. This review elucidates how these drive tumor by modulating By dissecting regulatory dynamics context of this aims deepen understanding m6A-ncRNA interaction identify potential targets improve treatment efficacy.

Язык: Английский

Процитировано

0